Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price lifted by equities research analysts at Truist Financial from $140.00 to $145.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective suggests a potential upside of 3.78% from the stock’s current price.
Several other research analysts also recently commented on GILD. Needham & Company LLC lifted their price target on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Daiwa Capital Markets boosted their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. UBS Group upped their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday. Citigroup increased their target price on shares of Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Royal Bank Of Canada raised their target price on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $135.36.
Read Our Latest Research Report on GILD
Gilead Sciences Stock Down 0.9%
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the previous year, the company posted $2.02 earnings per share. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, equities research analysts anticipate that Gilead Sciences will post 7.95 EPS for the current year.
Insider Buying and Selling
In other news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 247,397 shares of company stock valued at $31,986,612. Insiders own 0.27% of the company’s stock.
Institutional Trading of Gilead Sciences
A number of institutional investors have recently bought and sold shares of GILD. GoalVest Advisory LLC boosted its position in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences in the third quarter valued at about $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the second quarter worth about $27,000. Financial Consulate Inc. grew its position in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares during the period. Finally, Putney Financial Group LLC grew its position in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.
Key Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Phase‑3 Trodelvy combo beat Keytruda + chemo in a pivotal study, sparking a sharp rally and renewed bullish debate about Gilead’s oncology upside. Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial
- Positive Sentiment: Multiple analyst upgrades/price‑target raises (Citigroup to $156, Truist, BMO, UBS commentary) are reinforcing buy-side momentum and likely supporting higher valuations in the near term. Citigroup adjusts price target on Gilead Sciences to 156 from 140; maintains buy rating
- Neutral Sentiment: Gilead will report Q4 & full‑year 2025 results on Feb 10 — a clear near‑term catalyst that could amplify either the positive trial reaction or reveal operational headwinds. Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
- Neutral Sentiment: News aggregator and investor‑attention pieces (Zacks, sector writeups) are boosting visibility but are not new fundamental information. Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
- Neutral Sentiment: Short‑interest data in the feed shows zero shares/NaN (likely a reporting artifact) — not a reliable signal for positioning or squeeze risk today.
- Negative Sentiment: CEO Daniel O’Day sold 115,640 shares (~$15.6M) in late January, reducing his holding ~17% — a notable insider sale that market participants may view as a short‑term negative or liquidity event. SEC filing: Form 4 — Daniel Patrick O’day sale
About Gilead Sciences
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
